Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage

Hiam Chemaitelly^{1

2

3}, Houssein H Ayoub⁴, Peter Coyle^{5

6

7}, Patrick Tang⁸, Hadi M Yassine^{6

9}, Hebah A Al-Khatib^{6

9}, Maria K Smatti^{6

9}, Mohammad R Hasan⁸, Zaina Al-Kanaani⁵, Einas Al-Kuwari⁵, Andrew Jeremijenko⁵, Anvar Hassan Kaleeckal⁵, Ali Nizar Latif⁵, Riyazuddin Mohammad Shaik⁵, Hanan F Abdul-Rahim¹⁰, Gheyath K Nasrallah^{6

9}, Mohamed Ghaith Al-Kuwari¹¹, Adeel A Butt^{12

5

13}, Hamad Eid Al-Romaihi¹⁴, Mohamed H Al-Thani¹⁴, Abdullatif Al-Khal⁵, Roberto Bertollini¹⁴, Laith J Abu-Raddad^{15

16

17

18}

Affiliations

¹ Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar. hsc2001@qatar-med.cornell.edu.
² World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation - Education City, Doha, Qatar. hsc2001@qatar-med.cornell.edu.
³ Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, New York, USA. hsc2001@qatar-med.cornell.edu.
⁴ Mathematics Program, Department of Mathematics, Statistics, and Physics, College of Arts and Sciences, Qatar University, Doha, Qatar.
⁵ Hamad Medical Corporation, Doha, Qatar.
⁶ Biomedical Research Center, Member of QU Health, Qatar University, Doha, Qatar.
⁷ Wellcome-Wolfson Institute for Experimental Medicine, Queens University, Belfast, United Kingdom.
⁸ Department of Pathology, Sidra Medicine, Doha, Qatar.
⁹ Department of Biomedical Science, College of Health Sciences, Member of QU Health, Qatar University, Doha, Qatar.
¹⁰ Department of Public Health, College of Health Sciences, QU Health, Qatar University, Doha, Qatar.
¹¹ Primary Health Care Corporation, Doha, Qatar.
¹² Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, New York, USA.
¹³ Department of Medicine, Weill Cornell Medicine, Cornell University, New York, New York, USA.
¹⁴ Ministry of Public Health, Doha, Qatar.
¹⁵ Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar. lja2002@qatar-med.cornell.edu.
¹⁶ World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation - Education City, Doha, Qatar. lja2002@qatar-med.cornell.edu.
¹⁷ Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, New York, USA. lja2002@qatar-med.cornell.edu.
¹⁸ Department of Public Health, College of Health Sciences, QU Health, Qatar University, Doha, Qatar. lja2002@qatar-med.cornell.edu.

PMID: 35945213
PMCID: PMC9362989
DOI: 10.1038/s41467-022-32363-4

Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage

Hiam Chemaitelly et al. Nat Commun. 2022.

. 2022 Aug 9;13(1):4675.

doi: 10.1038/s41467-022-32363-4.

Authors

Affiliations

¹ Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar. hsc2001@qatar-med.cornell.edu.
² World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation - Education City, Doha, Qatar. hsc2001@qatar-med.cornell.edu.
³ Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, New York, USA. hsc2001@qatar-med.cornell.edu.
⁴ Mathematics Program, Department of Mathematics, Statistics, and Physics, College of Arts and Sciences, Qatar University, Doha, Qatar.
⁵ Hamad Medical Corporation, Doha, Qatar.
⁶ Biomedical Research Center, Member of QU Health, Qatar University, Doha, Qatar.
⁷ Wellcome-Wolfson Institute for Experimental Medicine, Queens University, Belfast, United Kingdom.
⁸ Department of Pathology, Sidra Medicine, Doha, Qatar.
⁹ Department of Biomedical Science, College of Health Sciences, Member of QU Health, Qatar University, Doha, Qatar.
¹⁰ Department of Public Health, College of Health Sciences, QU Health, Qatar University, Doha, Qatar.
¹¹ Primary Health Care Corporation, Doha, Qatar.
¹² Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, New York, USA.
¹³ Department of Medicine, Weill Cornell Medicine, Cornell University, New York, New York, USA.
¹⁴ Ministry of Public Health, Doha, Qatar.
¹⁵ Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar. lja2002@qatar-med.cornell.edu.
¹⁶ World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation - Education City, Doha, Qatar. lja2002@qatar-med.cornell.edu.
¹⁷ Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, New York, USA. lja2002@qatar-med.cornell.edu.
¹⁸ Department of Public Health, College of Health Sciences, QU Health, Qatar University, Doha, Qatar. lja2002@qatar-med.cornell.edu.

PMID: 35945213
PMCID: PMC9362989
DOI: 10.1038/s41467-022-32363-4

Abstract

There is significant genetic distance between SARS-CoV-2 Omicron (B.1.1.529) variant BA.1 and BA.2 sub-lineages. This study investigates immune protection of infection with one sub-lineage against reinfection with the other sub-lineage in Qatar during a large BA.1 and BA.2 Omicron wave, from December 19, 2021 to March 21, 2022. Two national matched, retrospective cohort studies are conducted to estimate effectiveness of BA.1 infection against reinfection with BA.2 (N = 20,994; BA.1-against-BA.2 study), and effectiveness of BA.2 infection against reinfection with BA.1 (N = 110,315; BA.2-against-BA.1 study). Associations are estimated using Cox proportional-hazards regression models after multiple imputation to assign a sub-lineage status for cases with no sub-lineage status (using probabilities based on the test date). Effectiveness of BA.1 infection against reinfection with BA.2 is estimated at 94.2% (95% CI: 89.2-96.9%). Effectiveness of BA.2 infection against reinfection with BA.1 is estimated at 80.9% (95% CI: 73.1-86.4%). Infection with the BA.1 sub-lineage appears to induce strong, but not full immune protection against reinfection with the BA.2 sub-lineage, and vice versa, for at least several weeks after the initial infection.

PubMed Disclaimer

Conflict of interest statement

Dr. Butt has received institutional grant funding from Gilead Sciences unrelated to the work presented in this paper. Otherwise, we declare no competing interests.

Figures

**Fig. 1. Distribution of SARS-CoV-2 BA.1 versus BA.2 Omicron infections.**
Proportion of BA.1 (versus BA.2) Omicron infections in PCR-positive tests assessed using TaqPath COVID-19 Combo Kit during the study period.

**Fig. 2. Population selection process.**
Cohort selection in the BA.1-against-BA.2 and BA.2-against-BA.1 studies.

**Fig. 3. Cumulative incidence of Omicron infections in the BA.1-against-BA.2 and BA.2-against-BA.1 studies.**
Cumulative incidence of a BA.2 and b BA.1 Omicron infections in the BA.1-against-BA.2 and BA.2-against-BA.1 studies, respectively. a includes 21,145 biologically independent samples for each of the BA.1-infected and the uninfected-control cohorts. b includes 110,315 biologically independent samples for each of the BA.2-infected and the uninfected-control cohorts.

See this image and copyright information in PMC

References

1. Cromer D, et al. Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. Nat. Rev. Immunol. 2021;21:395–404. doi: 10.1038/s41577-021-00550-x. - DOI - PMC - PubMed
1. World Health Organization. Tracking SARS-CoV-2 variants. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ (2021).
1. Schmidt F, et al. Plasma neutralization of the SARS-CoV-2 Omicron variant. N. Engl. J. Med. 2022;386:599–601. doi: 10.1056/NEJMc2119641. - DOI - PMC - PubMed
1. Planas D, et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2022;602:671–675. doi: 10.1038/s41586-021-04389-z. - DOI - PubMed
1. Chemaitelly H, Bertollini R, Abu-Raddad LJ. National Study Group for Covid epidemiology. efficacy of natural immunity against SARS-CoV-2 reinfection with the beta variant. N. Engl. J. Med. 2021;385:2585–2586. doi: 10.1056/NEJMc2110300. - DOI - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage

Affiliations

Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

References

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous